• Biomarker of Early-stage Aggressive Colon Cancer

Biomarker of Early-stage Aggressive Colon Cancer

Lack of the biomarker CDX2 identifies a subgroup of patients with high-risk stage II colon cancer who appeared to benefit from adjuvant chemotherapy. These patients are usually treated with surgery alone. The findings come from a study published online January 21 in the New England Journal of Medicine. Piero Dalerba

Read more